Acorda Therapeutics, Inc. (NASDAQ:ACOR) Files An 8-K Other Events
Item 8.01Other Events
On May 18, 2017, Acorda Therapeutics, Inc. (the Company) issued a
press release announcing that it will present new data from the
Phase 3 clinical trial of INBRIJATM (levodopa
inhalation powder) at the International Congress of Parkinsons
Disease and Movement Disorders (MDS), being held in Vancouver,
British Columbia from June 4-8, 2017. The Company is developing
INBRIJA (CVT-301) as a treatment for symptoms of OFF periods in
people with Parkinsons disease taking a carbidopa / levodopa
regimen. OFF periods refer to the re-emergence of Parkinsons
symptoms. A copy of the press release is attached as Exhibit 99.1
to this Current Report on Form 8-K, and is incorporated by
reference into this Item.
Item 9.01Financial Statements and Exhibits
(d) Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated May 18, 2017 |
About Acorda Therapeutics, Inc. (NASDAQ:ACOR)
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza. Its research and development programs include CVT-301, Dalfampridine, Plumiaz, Neuregulin Program, Remyelinating Antibodies Program, CVT-427 and Chondroitinase Program. Its Ampyra is an oral drug for the treatment to improve walking in patients with multiple sclerosis. Zanaflex Capsules and tablets are used as short-acting drugs for the management of spasticity. Qutenza is a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. Its pipeline of neurological therapies addresses a range of disorders, including Parkinson’s disease, chronic post-stroke walking deficits and migraine. Acorda Therapeutics, Inc. (NASDAQ:ACOR) Recent Trading Information
Acorda Therapeutics, Inc. (NASDAQ:ACOR) closed its last trading session down -0.50 at 15.00 with 656,215 shares trading hands.
